RCKT (Rocket Pharmaceuticals) DeferredTaxAndRevenue: $0.00 Mil (As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
25 GF Score
Price $3.97
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals DeferredTaxAndRevenue?

Rocket Pharmaceuticals RCKT +3.91% 25 DeferredTaxAndRevenue is $0.00 Mil as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Rocket Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

Rocket Pharmaceuticals DeferredTaxAndRevenue Related Terms

Rocket Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals DeferredTaxAndRevenue Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RCKT
25GF Score
Rocket Pharmaceuticals Inc RCKT
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Rocket Pharmaceuticals (RCKT) has a DeferredTaxAndRevenue of $0.00 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Rocket Pharmaceuticals.
Is Rocket Pharmaceuticals' DeferredTaxAndRevenue too high?
Rocket Pharmaceuticals' current DeferredTaxAndRevenue is $0.00 Mil. Overall, Rocket Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' DeferredTaxAndRevenue compare to TENX and DMAC?
Rocket Pharmaceuticals' DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Rocket Pharmaceuticals. Rocket Pharmaceuticals's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Rocket Pharmaceuticals' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current DeferredTaxAndRevenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
25GF Score

Get the complete analysis for RCKT

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price